今村 俊彦准教授

専門領域 小児血液学／造血器腫瘍／分子生物学／造血幹細胞移植
学会認定医
  • 日本小児科学会専門医
  • 日本血液学会血液専門医・指導医
  • 日本小児血液がん学会専門医・指導医
  • 骨髄移植財団移植調整医師
  • 造血細胞移植認定医

経歴

  • 平成6年3月

    京都府立医科大学卒業

  • 平成6年5月

    京都府立医科大学小児科研修医

  • 平成14年3月

    京都府立医科大学大学院修了

  • 平成14年4月

    明石市民病院小児科

  • 平成15年4月

    松下記念病院小児科

  • 平成16年9月

    シカゴ大学内科血液腫瘍部門博士研究員

  • 平成18年9月

    京都府立医科大学小児科学教室助教

  • 平成20年7月

    京都府立医科大学小児科学教室学内講師

  • 平成25年4月

    京都府立医科大学小児科学教室　講師

  • 令和4年10月

    京都府立医科大学小児科学教室　准教授　現在に至る

受賞歴

  • 平成15年

    第13回京都府立医科大学学友会青蓮賞

  • 平成24年

    小児医学研究振興財団研究助成

  • 平成25年

    公益信託日本白血病研究基金一般研究賞（クレディセゾン賞）

  • 令和2年

    公益信託日本白血病研究基金一般研究賞（清水賞）

学会役員歴

  • 日本小児科学会：代議員・英文誌編集委員
  • 日本血液学会：評議員・英文誌編集委員
  • 日本小児血液がん学会：評議委員・診療ガイドライン委員（委員長）・教育研修委員
  • NPO法人日本小児がん研究グループ（JCCG）：監査委員
  • NPO法人日本小児白血病研究会（JACLS）：運営委員長
  • NPO法人LCH研究会理事

研究内容

  1. 小児難治性白血病の遺伝子解析と治療標的の探索

  2. KMT2A融合遺伝子陽性白血病のCAR-T療法の開発

代表的論文

  1. Suematsu M, Yagyu S, Yoshida H, Osone S, Nakazawa Y, Sugita K, Imamura T, Iehara T. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. Cancer Immunol Immunother. 2022 Oct 10. doi: 10.1007/s00262-022-03303-4.

  2. Mayumi A, Tomii T, Kanayama T, Mikami T, Tanaka K, Ueno H, Yoshida H, Kato I, Kawamura M, Nakahata T, Takita J, Hosoi H, Imamura T. The combination of ruxolitinib and Bcl-2/Mcl-1 inhibitors has a synergistic effect on leukemic cells carrying a SPAG9::JAK2 fusion. Cancer Gene Ther. 2022 Jul 25. doi: 10.1038/s41417-022-00511-z.

  3. Tomii T, Imamura T, Tanaka K, Kato I, Mayumi A, Soma E, Yano M, Sakamoto K, Mikami T, Morita M, Kiyokawa N, Horibe K, Adachi S, Nakahata T, Takita J, Hosoi H. Leukemic cells expressing NCOR1-LYN are sensitive to dasatinib in vivo in a patient-derived xenograft mouse model. Leukemia. 2020 Nov 16. doi: 10.1038/s41375-020-01091-3.

  4. Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS). Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02. Blood Cancer J. 10(2): 23, 2020.

  5. Tomizawa D, Miyamura T, Imamura T, Watanabe T, Saito A, Ogawa A, Takahashi Y, Hirayama M, Taki T, Deguchi T, Hori T, Sanada M, Ohmori S, Haba M, Iguchi A, Arakawa Y, Koga Y, Manabe A, Horibe K, Ishii E, Koh K. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 136(16): 1813-1823, 2020.

  6. Kanayama T, Imamura T, Mayumi A, Soma E, Sakamoto K, Hayakawa F, Tanizawa A, Kiyokawa N, Hosoi H. Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient. Int J Hematol. 112(5): 714-719, 2020.

  7. Sakamoto K, Shiba N, Deguchi T, Kiyokawa N, Hashii Y, Moriya-Saito A, Tomizawa D, Taga T, Adachi S, Horibe K, Imamura T. Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. Br J Haematol. 187(3): 372-376, 2019.

  8. Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, Kanno M, Mori T, Hiramatsu H, Matsubara K, Terui K, Takahashi Y, Suenobu SI, Hasegawa D, Kosaka Y, Kato K, Moriya-Saito A, Sato A, Kawasaki H, Yumura-Yagi K, Hara J, Hori H, Horibe K. Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 study of Japan Association of Childhood Leukemia Study Group. J Clin Oncol. 36(9): 900-907, 2018.

  9. Imamura T, Taga T, Takagi M, Kawasaki H, Koh K, Taki T, Adachi S, Manabe A, Ishida Y; Leukemia/Lymphoma Committee; Japanese Society of Pediatric Hematology Oncology (JSPHO). Nationwide survey of therapy-related leukemia in childhood in Japan. Int J Hematol. 108(1): 91-97, 2018.

  10. Imamura T, Kiyokawa N, Kato M, Imai C, Okamoto Y, Yano M, Ohki K, Yamashita Y, Kodama Y, Saito A, Mori M, Ishimaru S, Deguchi T, Hashii Y, Shimomura Y, Hori T, Kato K, Goto H, Ogawa C, Koh K, Taki T, Manabe A, Sato A, Kikuta A, Adachi S, Horibe K, Ohara A, Watanabe A, Kawano Y, Ishii E, Shimada H. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J. 6: e419, 2016.

  11. Imamura T, Yano M, Asai D, Moriya-Saito A, Suenobu S-I, Hasegawa D, Deguchi T, Hashii Y, Kawasaki H, Hori H, Yumura-Yagi K, Hara J, Horibe K, Sato A. IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance. Leukemia. 30(8): 1801-1803, 2016

  12. Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O'Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ. Instructive role of MLL-fusion proteins revealed by a model of t(4;11) pro-B acute lymphoblastic leukemia. Cancer Cell. 30(5): 737-749, 2016.

  13. Yano M, Imamura T, Asai D, Kiyokawa N, Nakabayashi K, Matsumoto K, Deguchi T, Hashii Y, Honda YK, Hsegawa D, Sasahara Y, Ishii M, Kosaka Y, Kato K, Shima M, Hori H, Yumura-Yagi K, Hara J, Oda M, Horibe K, Ichikawa H, Sato A. Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion. Br J Haematol. 2015 Sep 25. doi: 10.1111/bjh.13757.

  14. Kawashima-Goto S, Imamura T, Tomoyasu C, Yano M, Yoshida H, Fujiki A, Tamura S, Osone S, Ishida H, Morimoto A, Kuroda H, Hosoi H. BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression? PLoS One. 10(7): e0132926, 2015. doi: 10.1371/journal.pone.0132926.

  15. Yano M, Imamura T, Asai D, Moriya-Saito A, Suenobu SI, Hasegawa D, Deguchi T, Hashii Y, Kawasaki H, Hori H, Kosaka Y, Kato K, Horibe K, Yumura-Yagi K, Hara J, Matsumoto K, Kiyokawa N, Oda M, Sato A; for the Japan Association of Childhood Leukemia Study (JACLS). An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression. Genes Chromosomes Cancer. 2014; 53(10):815-23

  16. Sakamoto K, Imamura T, Yano M, Yoshida H, Fujiki A, Hirashima Y, Hosoi H. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region. Blood Cancer Journal 4, e205; doi:10.1038/bcj.2014.25, 2014.

  17. Asai D, Imamura T, Yamashita Y, Suenobu S, Moriya-Saito A, Hasegawa D, Deguchi T, Hashii Y, Endo M, Hatakeyama N, Kawasaki H, Hori H, Horibe K, Yumura-Yagi K, Hara J, Watanabe A, Ki Kikuta A, Oda M, Sato A. Outcome of TCF3-PBX1 positive pediatric acute lymphoblastic leukemia patients in Japan: a collaborative study of Japan Association of Childhood Leukemia Study and Children's Cancer and Leukemia Study Group. Cancer Medicine doi: 10.1002/cam4.221, 2014.

  18. Asai D, Imamura T, Suenobu S, Saito A, Hasegawa D, Deguchi T, Hashii Y, Matsumoto K, Kawasaki H, Hori H, Iguchi A, Kosaka Y, Kato K, Horibe K, Yumura-Yagi K, Hara J, Oda M. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan. Cancer Medicine. 2: 412-419, 2013

  19. Imamura T, Morimoto A, Takanashi M, Hibi S, Sugimoto T, Ishii E, Imashuku S. Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement. Br J Haematol. 119(1): 119-121, 2002.

  20. Imamura T, Morimoto A, Ikushima S, Kakazu N, Hada S, Tabata Y, Yagi T, Inaba T, Hibi S, Sugimoto T, Imashuku S. A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript. Leukemia. 16(11): 2302-2308, 2002.